A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC -X Trial).

被引：11
作者：
Gonzalez, Maria
Hong, Angela M.
Carlino, Matteo S.
Atkinson, Victoria
Wang, Wei
Lo, Serigne
Brown, Michael Paul
Foote, Matthew C.
Pinkham, Mark B.
Le, Hien
Roos, Daniel E.
Osorio, Monica
Haghighi, Neda
Kok, David
Postow, Michael A.
McArthur, Grant A.
Menzies, Alexander M.
Long, Georgina V.
机构：
[1] Melanoma Inst Australia, Sydney, NSW, Australia
[2] Univ Sydney, Chris OBrien Lifehouse, Melanoma Inst Australia, Sydney, NSW, Australia
[3] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[4] Univ Sydney, Blacktown Hosp, Melanoma Inst Australia, Sydney, NSW, Australia
[5] Univ Queensland, Gallipoli Med Res Fdn, Princess Alexandra Hosp, Woolloongabba, Qld, Australia
[6] Westmead Hosp, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[7] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[8] Royal Adelaide Hosp, Adelaide, SA, Australia
[9] Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld, Australia
[10] Univ Queensland, Queensland Univ Technol, Gamma Knife Ctr Queensland, Princess Alexandra Hosp, Woolloongabba, Qld, Australia
[11] Univ Adelaide, Royal Adelaide Hosp, Adelaide, SA, Australia
[12] Melanoma Inst Australia, Sydney, NSW, Australia
[13] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[15] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[16] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, Sydney, NSW, Australia
[17] Royal North Shore Hosp, Sydney, NSW, Australia
[18] Mater Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS9600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9600
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018)
    Hodi, F. S.
    Chiarion-Sileni, V
    Gonzalez, R.
    LANCET ONCOLOGY, 2018, 19 (12) : E668 - E668
  • [32] A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone.
    Pili, Roberto
    Adra, Nabil
    Logan, Theodore F.
    Burney, Heather
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [33] Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
    Ascierto, Paolo A. A.
    Mandala, Mario
    Ferrucci, Pier Francesso
    Guidoboni, Massimo
    Rutkowski, Piotr
    Ferraresi, Virginia
    Arance, Ana
    Guida, Michele
    Maiello, Evaristo
    Gogas, Helen
    Richtig, Erika
    Fierro, Maria Teresa
    Lebbe, Celeste
    Helgadottir, Hildur
    Queirolo, Paola
    Spagnolo, Francesco
    Tucci, Marco
    Del Vecchio, Michele
    Gonzales Cao, Maria
    Minisini, Alessandro Marco
    De Placido, Sabino
    Sanmamed, Miguel F. F.
    Mallardo, Domenico
    Curvietto, Marcello
    Melero, Ignacio
    Palmieri, Giuseppe
    Grimaldi, Antonio M.
    Giannarelli, Diana
    Dummer, Reinhard
    Sileni, Vanna Chiarion
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 212 - +
  • [34] Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma
    Weber, J. S.
    Muramatsu, T.
    Hamid, O.
    Mehnert, J.
    Hodi, F. S.
    Krishnarajapet, S.
    Malatyali, S.
    Buchbinder, E.
    Goldberg, J.
    Sullivan, R.
    Faries, M.
    Mehmi, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S869 - S869
  • [35] A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).
    Long, Georgina V.
    Atkinson, Victoria
    Menzies, Alexander M.
    Lo, Serigne
    Guminski, Alexander David
    Brown, Michael Paul
    Gonzalez, Maria Magdalena
    Diamante, Katrina
    Sandhu, Shahneen Kaur
    Scolyer, Richard A.
    Emmett, Louise
    McArthur, Grant A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in hemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC)
    Paz-Ares, L.
    Brahmer, J.
    Hellmann, M. D.
    Reck, M.
    O'Byrne, K.
    Borghaei, H.
    Geese, W. J.
    Lu, H.
    Nathan, F. E.
    Ramalingam, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
    Antonia, Scott J.
    Lopez-Martin, Jose A.
    Bendell, Johanna
    Ott, Patrick A.
    Taylor, Matthew
    Eder, Joseph Paul
    Jaeger, Dirk
    Pietanza, M. Catherine
    Le, Dung T.
    de Braud, Filippo
    Morse, Michael A.
    Ascierto, Paolo A.
    Horn, Leora
    Amin, Asim
    Pillai, Rathi N.
    Evans, Jeffry
    Chau, Ian
    Bono, Petri
    Atmaca, Akin
    Sharma, Padmanee
    Harbison, Christopher T.
    Lin, Chen-Sheng
    Christensen, Olaf
    Calvo, Emiliano
    LANCET ONCOLOGY, 2016, 17 (07) : 883 - 895
  • [38] Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
    Di Giacomo, A. M.
    Sileni, V. Chiarion
    Del Vecchio, M.
    Ferrucci, P. F.
    Guida, M.
    Quaglino, P.
    Guidoboni, M.
    Marchetti, P.
    Cutaia, O.
    Amato, G.
    Gambale, E.
    Calabro, L.
    Valente, M.
    Danielli, R.
    Giannarelli, D.
    Mandala, M.
    Maio, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S734 - S734
  • [39] Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis
    Cui, Shuting
    Sun, Xiaozhe
    Gao, Junxi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (05) : 283 - 291
  • [40] Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
    Joris L. Vos
    Bharat Burman
    Swati Jain
    Conall W. R. Fitzgerald
    Eric J. Sherman
    Lara A. Dunn
    James V. Fetten
    Loren S. Michel
    Anuja Kriplani
    Kenneth K. Ng
    Juliana Eng
    Vatche Tchekmedyian
    Sofia Haque
    Nora Katabi
    Fengshen Kuo
    Catherine Y. Han
    Zaineb Nadeem
    Wei Yang
    Vladimir Makarov
    Raghvendra M. Srivastava
    Irina Ostrovnaya
    Manu Prasad
    Charlotte L. Zuur
    Nadeem Riaz
    David G. Pfister
    Christopher A. Klebanoff
    Timothy A. Chan
    Alan L. Ho
    Luc G. T. Morris
    Nature Medicine, 2023, 29 : 3077 - 3089
12345